Linked Life Data

17230535

Source:http://linkedlifedata.com/resource/pubmed/id/17230535

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17230535rdf:typepubmed:Citationlld:pubmed
pubmed-article:17230535lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C0017638lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C0020852lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C0041361lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C1420328lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C0332183lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:17230535lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:17230535pubmed:issue8lld:pubmed
pubmed-article:17230535pubmed:dateCreated2007-3-13lld:pubmed
pubmed-article:17230535pubmed:abstractTextWe previously reported to identify SOX5 as a glioma antigen by serological screening using a testis cDNA library. The present study was designed to analyze SOX5 expression, its immunoreactivity, and the correlation between SOX5 IgG responses and clinical features in glioma patients to evaluate the possibility of its use as a diagnostic marker. Quantitative RT-PCR and Western blot analysis revealed that SOX5 was expressed in glioma tissues, but not in normal adult tissues, except in the testis. An immunohistochemical analysis showed that SOX5 was expressed in glioma cells, but only a few SOX5-positive cells were detected in non-neoplastic tissues from the cerebral cortex. IgG antibodies against SOX5 were detected in sera from 8 of the 27 glioma patients (27.6%), 0 of the 14 patients with other brain diseases (0%), 1 of the 54 other cancer patients (1.9%) and 1 of the 37 healthy individuals (2.7%). Patients with glioblastoma (GBM) who showed IgG responses against SOX5 exhibited significantly better survival periods than GBM patients without SOX5 antibodies. In summary, SOX5 is aberrantly expressed in glioma and can be recognized as a glioma antigen using IgGs from the sera of glioma patients. Furthermore, there is a statistically significant correlation between the presence of SOX5 IgGs and survival in GBM patients, suggesting that the glioma antigen SOX5 may be useful not only as a diagnostic marker, but also as a prognostic marker in glioma patients.lld:pubmed
pubmed-article:17230535pubmed:languageenglld:pubmed
pubmed-article:17230535pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17230535pubmed:citationSubsetIMlld:pubmed
pubmed-article:17230535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17230535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17230535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17230535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17230535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17230535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17230535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17230535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17230535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17230535pubmed:statusMEDLINElld:pubmed
pubmed-article:17230535pubmed:monthAprlld:pubmed
pubmed-article:17230535pubmed:issn0020-7136lld:pubmed
pubmed-article:17230535pubmed:authorpubmed-author:KawaseTakeshi...lld:pubmed
pubmed-article:17230535pubmed:authorpubmed-author:YoshidaKazuna...lld:pubmed
pubmed-article:17230535pubmed:authorpubmed-author:TodaMasahiroMlld:pubmed
pubmed-article:17230535pubmed:authorpubmed-author:KawakamiYutak...lld:pubmed
pubmed-article:17230535pubmed:authorpubmed-author:UedaRyoRlld:pubmed
pubmed-article:17230535pubmed:copyrightInfo(c) 2007 Wiley-Liss, Inc.lld:pubmed
pubmed-article:17230535pubmed:issnTypePrintlld:pubmed
pubmed-article:17230535pubmed:day15lld:pubmed
pubmed-article:17230535pubmed:volume120lld:pubmed
pubmed-article:17230535pubmed:ownerNLMlld:pubmed
pubmed-article:17230535pubmed:authorsCompleteYlld:pubmed
pubmed-article:17230535pubmed:pagination1704-11lld:pubmed
pubmed-article:17230535pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:meshHeadingpubmed-meshheading:17230535...lld:pubmed
pubmed-article:17230535pubmed:year2007lld:pubmed
pubmed-article:17230535pubmed:articleTitlePreferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients.lld:pubmed
pubmed-article:17230535pubmed:affiliationNeuroimmunology Research Group, Keio University School of Medicine, Tokyo 160-8582, Japan.lld:pubmed
pubmed-article:17230535pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17230535pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:17230535pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:6660entrezgene:pubmedpubmed-article:17230535lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17230535lld:entrezgene
lhgdn:association:24143lhgdn:found_inpubmed-article:17230535lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17230535lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17230535lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17230535lld:pubmed